Effect Of Pioglitazone On Inflammatory Response And Clinical Outcome In T2DM Patients With COVID-19: A Randomized Multicenter Double-Blind Clinical Trial
Frontiers in Immunology This study, drawing data from Kuwait and Qatar, evaluates the efficacy of pioglitazone, a strong insulin sensitizer with anti-inflammatory properties, in improving the clinical outcomes of patients with type 2 diabetes admitted with moderate-severe COVID-19. Journal Article
Read More